Related Experiment Videos
Interferon beta-1a in children with multiple sclerosis is well tolerated
E Waubant1, J Hietpas, T Stewart
1UCSF/Mt Zion Multiple Sclerosis Center, San Francisco, CA, USA. emmanuelle.waubant@psl.ap-hop-paris.fr
Neuropediatrics
|September 26, 2001
Summary
Weekly interferon beta-1a (IFNB-1 a) injections were well tolerated in children with relapsing-remitting multiple sclerosis (RRMS). No patients discontinued treatment due to adverse events, suggesting a favorable safety profile for pediatric MS management.
Area of Science:
- Neurology
- Pediatric Medicine
- Immunology
Background:
- Multiple sclerosis (MS) is a chronic demyelinating neurological disorder.
- Pediatric MS is rare, and treatment options for children are limited.
- Current disease-modifying therapies for MS are primarily approved for adult use.
Purpose of the Study:
- To assess the tolerability of interferon beta-1a (IFNB-1 a) in pediatric patients with relapsing-remitting MS (RRMS).
- To evaluate the safety and feasibility of weekly intramuscular IFNB-1 a injections in children under 16 years old.
Main Methods:
- A survey was distributed to US neurologists to gather data on IFNB-1 a tolerability in pediatric MS patients.
- Data were collected from neurologists who initiated IFNB-1 a treatment in patients younger than 16 years.
- Tolerability was assessed based on treatment continuation and reasons for discontinuation.
Main Results:
- Tolerability data were obtained for 9 pediatric patients initiating IFNB-1 a treatment.
- The mean age of patients starting treatment was 12.7 years, with a treatment duration averaging 17 months.
- No patients discontinued IFNB-1 a therapy due to adverse events, indicating good tolerability.
Conclusions:
- Weekly intramuscular IFNB-1 a injections demonstrate preliminary tolerability in children with RRMS.
- The findings suggest IFNB-1 a may be a viable treatment option for pediatric MS patients.
- Further research is warranted to confirm long-term efficacy and safety in this population.